Advertisement

FDA Approves Dalbavancin to Treat Acute Bacterial Skin Infections — Physician’s First Watch

Medical News |
May 27, 2014

FDA Approves Dalbavancin to Treat Acute Bacterial Skin Infections

By Amy Orciari Herman

The FDA has approved dalbavancin (marketed as Dalvance) to treat adults with skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

The intravenous drug is given in two doses, 1 week apart. In randomized trials, it was as effective as the antibiotic vancomycin. The most common side effects were nausea, headache, and diarrhea. Dalbavancin recipients were more likely than vancomycin recipients to have elevated liver enzymes.

Dalbavancin's label includes guidance on dosage adjustments for patients with renal impairment.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement